Can vepotuzumab (POLIVY) cure tumors?

Vepotolizumab (POLIVY) belongs to a new class of cancer therapies called antibody-drug conjugates (ADCs) in development. Antibody-drug conjugates target tumor-associated antigens. They consist of monoclonal antibodies that selectively bind to tumor-associated antigens and then release cytotoxins to specifically kill tumor cells. CD30-directed velpotuzumab is the first ADC established for the treatment of hematologic malignancies, specifically Hodgkin's lymphoma.

Vepotolizumab is the first ADC approved by the FDA for the treatment of diffuse large B-cell lymphoma (DLBCL), consisting of the antimitotic cytotoxic agent monomethyl auristatin E. (MMAE), which is linked to a monoclonal antibody that selectively binds to cell surface CD79b (Deeks). Upon binding, the linker is cleaved, releasing MMAE into the cell where it inhibits division and induces apoptosis. VepotuzumabWhen combined with chemotherapy in the treatment of diffuse large B-cell lymphoma, it can increase the effectiveness of treatment and improve survival in patients, some of whom go 12 months or longer without evidence of lymphoma.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.